drugset / Trial / NCT04372355

Effect of WF10 (TCDO) on HbA1c Values in Diabetic Foot Ulcer Patients

NCT04372355

NaSingle-groupOpen-labelTreatment

Summary

Study in adult Diabetes Mellitus patients with diabetic foot ulcers and elevated HbA1c who will receive standard wound treatment in combination with adjuvant therapy WF10 to compare the change of HbA1c levels at baseline and after treatment.

Timeline

Start
2019-06-19
Primary completion
2020-04-30
Completion
2020-06-19

Drugs

EvaluationDrugModalityDoseRoute
Subject WF10 Other / unclassified 0.3 unknown Intravenous

Indications